Literature DB >> 16152623

Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line.

Michael L Roberts1, Konstantinos G Drosopoulos, Ioannis Vasileiou, Mona Stricker, Era Taoufik, Christian Maercker, Apostolia Guialis, Michael N Alexis, Alexander Pintzas.   

Abstract

Colorectal cancer arises after a series of mutational events in the colon epithelia and is often used as a model of the multistep progression of tumorigenesis. Mutations in Ki-Ras have been detected in some 50% of cases and are thought to occur at an early stage. Almost never do mutations arise in the loci of other Ras isoforms (Ha- and N-), leading to the assumption that Ki-Ras plays a unique role in tumorigenesis. In order to examine the distinctive function that Ki-Ras plays in cancer development in the colon, we introduced constitutively active mutant Ki- and Ha-Ras genes into an intermediate-stage colon adenoma cell line (Caco-2). We found that mutant active Ha-RasV12 was more efficient at transforming these colon epithelial cells as assessed by anchorage-independent growth, tumor formation in SCID mice and the development of mesenchymal morphology compared to transformation by Ki-RasV12. We conducted microarray analysis in an attempt to reveal the genes whose aberrant expression is a direct result of overexpression of either Ki-RasV12 or Ha-RasV12. We used Clontech's Atlas cancer cDNA (588 genes) and RZPD's Onco Set 1 (1,544 genes) arrays. We identified fewer genes that were commonly regulated than were differentially expressed between Ki- and Ha-RasV12 isoforms. Specifically, we found that Ki-RasV12 regulated genes involved in cytokine signaling, cell adhesion and colon development, whereas Ha-RasV12 mainly regulated genes involved in controlling cell morphology, correlating to an epithelial-mesenchymal transition only observed in these cells. Our results demonstrate how 2 Ras isoforms regulate disparate biologic processes, revealing a number of genes whose deregulated expression may influence colon carcinogenesis (supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html). Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16152623     DOI: 10.1002/ijc.21386

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Functional specificity of ras isoforms: so similar but so different.

Authors:  Esther Castellano; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

2.  BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.

Authors:  Eftychia Oikonomou; Eleni Makrodouli; Maria Evagelidou; Tobias Joyce; Lesley Probert; Alexander Pintzas
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

3.  A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis.

Authors:  Tobias Joyce; Daniela Cantarella; Claudio Isella; Enzo Medico; Alexander Pintzas
Journal:  Clin Exp Metastasis       Date:  2009-04-02       Impact factor: 5.150

4.  Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGΒ4-PDCD4) as predictor of metastatic tumor potential.

Authors:  Angelo Ferraro; Christos K Kontos; Themis Boni; Ioannis Bantounas; Dimitra Siakouli; Vivian Kosmidou; Margarita Vlassi; Yannis Spyridakis; Iraklis Tsipras; George Zografos; Alexander Pintzas
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

5.  Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.

Authors:  Margaret P Quinlan; Steven E Quatela; Mark R Philips; Jeffrey Settleman
Journal:  Mol Cell Biol       Date:  2008-02-11       Impact factor: 4.272

6.  Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.

Authors:  Eftychia Oikonomou; Michal Koc; Vladimira Sourkova; Ladislav Andera; Alexander Pintzas
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

7.  BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.

Authors:  Eleni Makrodouli; Eftychia Oikonomou; Michal Koc; Ladislav Andera; Takehiko Sasazuki; Senji Shirasawa; Alexander Pintzas
Journal:  Mol Cancer       Date:  2011-09-23       Impact factor: 27.401

8.  Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications.

Authors:  Sami S Azrak; Alicia Ginel-Picardo; Matthias Drosten; Mariano Barbacid; Eugenio Santos
Journal:  BMC Genomics       Date:  2013-10-25       Impact factor: 3.969

Review 9.  BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.

Authors:  Eftychia Oikonomou; Evangelos Koustas; Maria Goulielmaki; Alexander Pintzas
Journal:  Oncotarget       Date:  2014-12-15

10.  Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study.

Authors:  M Horsch; C V Recktenwald; S Schädler; M Hrabé de Angelis; B Seliger; J Beckers
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.